Fizazi K - Search Results

1

Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies.

Gravis G, Boher JM, Chen YH, Liu G, Fizazi K, Carducci MA, Oudard S, Joly F, Jarrard DM, Soulie M, Eisenberger MJ, Habibian M, Dreicer R, Garcia JA, Hussain MHM, Kohli M, Vogelzang NJ, Picus J, DiPaola R, Sweeney C. Gravis G, et al. Among authors: fizazi k. Eur Urol. 2018 Jun;73(6):847-855. doi: 10.1016/j.eururo.2018.02.001. Epub 2018 Feb 21. Eur Urol. 2018. PMID: 29475737 Free PMC article.

2

Evaluation of estramustine phosphate combined with weekly doxorubicin in patients with androgen-independent prostate cancer.

Culine S, Kattan J, Zanetta S, Théodore C, Fizazi K, Droz JP. Culine S, et al. Among authors: fizazi k. Am J Clin Oncol. 1998 Oct;21(5):470-4. doi: 10.1097/00000421-199810000-00010. Am J Clin Oncol. 1998. PMID: 9781602 Clinical Trial.

3

Is òne cycle every three or four weeks' obsolete? A critical review of dose-dense chemotherapy in solid neoplasms.

Fizazi K, Zelek L. Fizazi K, et al. Ann Oncol. 2000 Feb;11(2):133-49. doi: 10.1023/a:1008344014518. Ann Oncol. 2000. PMID: 10761747 Free article. Review.

4

Peritoneal carcinomatosis in germ-cell tumor: relations with retroperitoneal lymph node dissection.

Andre F, Fizazi K, Culine S, Droz JP, Gatineau M, Takahashi Y, Oudard S, Theodore C. Andre F, et al. Among authors: fizazi k. Am J Clin Oncol. 2000 Oct;23(5):460-2. doi: 10.1097/00000421-200010000-00006. Am J Clin Oncol. 2000. PMID: 11039504

5

The emerging role of antifolates in the treatment of malignant pleural mesothelioma.

Fizazi K, John WJ, Vogelzang NJ. Fizazi K, et al. Semin Oncol. 2002 Feb;29(1):77-81. doi: 10.1053/sonc.2002.30233. Semin Oncol. 2002. PMID: 11836672 Review.

6

A 10-year clinical experience with intermittent hormonal therapy for prostate cancer.

Prapotnich D, Fizazi K, Escudier B, Mombet A, Cathala N, Vallancien G. Prapotnich D, et al. Among authors: fizazi k. Eur Urol. 2003 Mar;43(3):233-39; discussion 239-40. doi: 10.1016/s0302-2838(03)00004-6. Eur Urol. 2003. PMID: 12600425

7

The role of Src in prostate cancer.

Fizazi K. Fizazi K. Ann Oncol. 2007 Nov;18(11):1765-73. doi: 10.1093/annonc/mdm086. Epub 2007 Apr 10. Ann Oncol. 2007. PMID: 17426060 Free article. Review.

8

Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data.

Fizazi K, Le Maitre A, Hudes G, Berry WR, Kelly WK, Eymard JC, Logothetis CJ, Pignon JP, Michiels S; Meta-analysis of Estramustine in Prostate Cancer (MECaP) Trialists' Collaborative Group. Fizazi K, et al. Lancet Oncol. 2007 Nov;8(11):994-1000. doi: 10.1016/S1470-2045(07)70284-X. Epub 2007 Oct 17. Lancet Oncol. 2007. PMID: 17942366

9

[Prostate cancer: future strategies for chemotherapy management].

Fizazi K. Fizazi K. Ann Urol (Paris). 2007 Oct;41 Suppl 3:S77-9. doi: 10.1016/s0003-4401(07)80514-6. Ann Urol (Paris). 2007. PMID: 18297905 Review. French.

10

Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer.

Italiano A, Ortholan C, Oudard S, Pouessel D, Gravis G, Beuzeboc P, Bompas E, Fléchon A, Joly F, Ferrero JM, Fizazi K. Italiano A, et al. Among authors: fizazi k. Eur Urol. 2009 Jun;55(6):1368-75. doi: 10.1016/j.eururo.2008.07.078. Epub 2008 Aug 8. Eur Urol. 2009. PMID: 18706755

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

520 results

Search Page